Biotech notches another $2B VC quarter, but can it last?

Damian Garde

venture capital investments remain on pace for a record year after racking up $ 2 billion in the third , but some current shakiness in the public markets could change the outlook for early-stage drug developers looking to fill their coffers in the future.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS